X4 Pharmaceuticals(XFOR)

Search documents
X4 Pharmaceuticals(XFOR) - 2020 Q2 - Quarterly Report
2020-08-04 20:37
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...
X4 Pharmaceuticals(XFOR) - 2020 Q2 - Earnings Call Transcript
2020-08-02 13:13
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Candice Ellis - Director, Corporate Communications & Investor Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Ellen Sands – Stifel Ben Shim – Canaccord Leland Gershell - Oppenheimer Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Laura Christianson - Cowen Zegbeh Jallah - ROTH Capital Partners Mayank Mamtani - B. ...
X4 Pharmaceuticals (XFOR) Presents At BMO Capital Markets Prescription For Success Healthcare Conference - Slideshow
2020-06-24 21:16
INVESTOR PRESENTATION JUNE 2020 X 4 P H A R M A C E U T I C A L S I N V E S T O R D E C K FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candida ...
X4 Pharmaceuticals (XFOR) Post-EHA Corporate Update - Slideshow
2020-06-12 20:56
EHA 2020 Poster Highlights June 12, 2020 Safe Harbor Statement 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain th ...
X4 Pharmaceuticals (XFOR) Investor Presentation - Slideshow
2020-06-03 22:14
INVESTOR PRESENTATION JUNE 2020 X4 PHARMACEUTICALS INVESTOR DECK FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candidates or to expand our oper ...
X4 Pharmaceuticals(XFOR) - 2020 Q1 - Earnings Call Transcript
2020-05-09 21:23
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Candice Ellis - Director of Corporate Communications & Investor Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Laura Christianson - Cowen Trevor Allred - Oppenheimer Sahil Kazmi - B. Riley FBR Arlinda Lee - Canaccord Operator Greetings, and w ...
X4 Pharmaceuticals(XFOR) - 2020 Q1 - Quarterly Report
2020-05-07 20:54
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...
X4 Pharmaceuticals(XFOR) - 2019 Q4 - Earnings Call Transcript
2020-03-12 22:22
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2019 Results Conference Call March 12, 2020 8:30 AM ET Company Participants Candice Ellis - IR Paula Ragan - CEO Lynne Kelley - CMO Adam Mostafa - CFO Conference Call Participants Stephen Willey - Stifel Arlinda Lee - Canaccord Genuity Marc Frahm - Cowen Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Alex Heller - Oppenheimer Zegbeh Jallah - ROTH Capital Partners Operator Greetings and welcome to X4 Pharmaceuticals Fourth Quarter and Full Year 2019 Busi ...
X4 Pharmaceuticals(XFOR) - 2019 Q4 - Annual Report
2020-03-12 20:59
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per ...
X4 Pharmaceuticals (XFOR) Presents At Cowen Health Care Conference - Slideshow
2020-03-05 11:29
INVESTOR PRESENTATION MARCH 2020 X 4 P H A R M A C E U T I C A L S I N V E S T O R D E C K FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, a ...